Skip to main content
NCBI home page
Journal of Neurology, Neurosurgery, and Psychiatry logoLink to Journal of Neurology, Neurosurgery, and Psychiatry
. 1995 Sep;59(3):243–247. doi: 10.1136/jnnp.59.3.243

Plasma exchange and chlorambucil in polyneuropathy associated with monoclonal IgM gammopathy. IgM-associated Polyneuropathy Study Group.

E Oksenhendler 1, S Chevret 1, J M Léger 1, J P Louboutin 1, A Bussel 1, J C Brouet 1
PMCID: PMC486020  PMID: 7673949

Abstract

The study compared chlorambucil alone with chlorambucil in combination with plasma exchange in patients with polyneuropathy associated with monoclonal IgM. Forty four patients were prospectively randomly assigned, in a comparative open trial, to receive either 0.1 mg/kg/day chlorambucil orally, for 12 months or chlorambucil associated with 15 courses of plasma exchange, during the first four months of treatment. They were evaluated by a neuropathy disability score and nerve conduction studies. No difference was found between the two treatment groups. The average neuropathy disability score improved by 2.1 points from baseline (21.0 to 18.9) in the chlorambucil group and by 1.8 points (20.4 to 18.6) in the chlorambucil + plasma exchange group (P = 0.70). The mean motor nerve conduction velocity decreased from 20.0 to 18.2 m/s in the chlorambucil group and increased from 20.5 to 22.5 m/s in the chlorambucil + plasma exchange group (P = 0.51). A slight improvement of the sensory component of the neuropathy disability score (from 10.5 to 8.3) was noted in both groups (P = 0.01). At the end of the study and according to self evaluation, 15 patients--eight from the chlorambucil group and seven from the chlorambucil + plasma exchange group--reported clinical improvement, whereas 15--eight from the chlorambucil group and seven from the chlorambucil + plasma exchange group--reported clinical worsening. Neuropathy remained stable in the others. Thus plasma exchange seemed to confer no additional benefit in the treatment of polyneuropathy associated with monoclonal IgM.

Full text

PDF
243

Selected References

These references are in PubMed. This may not be the complete list of references from this article.

  1. Braun P. E., Frail D. E., Latov N. Myelin-associated glycoprotein is the antigen for a monoclonal IgM in polyneuropathy. J Neurochem. 1982 Nov;39(5):1261–1265. doi: 10.1111/j.1471-4159.1982.tb12563.x. [DOI] [PubMed] [Google Scholar]
  2. Cook D., Dalakas M., Galdi A., Biondi D., Porter H. High-dose intravenous immunoglobulin in the treatment of demyelinating neuropathy associated with monoclonal gammopathy. Neurology. 1990 Feb;40(2):212–214. doi: 10.1212/wnl.40.2.212. [DOI] [PubMed] [Google Scholar]
  3. Dancea S., Dellagi K., Renaud F., Mahouy G., Hauw J. J., Brouet J. C. Effect of passive transfer of human anti-myelin-associated glycoprotein IgM in marmoset. Autoimmunity. 1989;3(1):29–37. doi: 10.3109/08916938909043611. [DOI] [PubMed] [Google Scholar]
  4. Dellagi K., Dupouey P., Brouet J. C., Billecocq A., Gomez D., Clauvel J. P., Seligmann M. Waldenström's macroglobulinemia and peripheral neuropathy: a clinical and immunologic study of 25 patients. Blood. 1983 Aug;62(2):280–285. [PubMed] [Google Scholar]
  5. Dyck P. J., Daube J., O'Brien P., Pineda A., Low P. A., Windebank A. J., Swanson C. Plasma exchange in chronic inflammatory demyelinating polyradiculoneuropathy. N Engl J Med. 1986 Feb 20;314(8):461–465. doi: 10.1056/NEJM198602203140801. [DOI] [PubMed] [Google Scholar]
  6. Dyck P. J. Intravenous immunoglobulin in chronic inflammatory demyelinating polyradiculoneuropathy and in neuropathy associated with IgM monoclonal gammopathy of unknown significance. Neurology. 1990 Feb;40(2):327–328. doi: 10.1212/wnl.40.2.327. [DOI] [PubMed] [Google Scholar]
  7. Dyck P. J., Low P. A., Windebank A. J., Jaradeh S. S., Gosselin S., Bourque P., Smith B. E., Kratz K. M., Karnes J. L., Evans B. A. Plasma exchange in polyneuropathy associated with monoclonal gammopathy of undetermined significance. N Engl J Med. 1991 Nov 21;325(21):1482–1486. doi: 10.1056/NEJM199111213252105. [DOI] [PubMed] [Google Scholar]
  8. Dyck P. J., Sherman W. R., Hallcher L. M., Service F. J., O'Brien P. C., Grina L. A., Palumbo P. J., Swanson C. J. Human diabetic endoneurial sorbitol, fructose, and myo-inositol related to sural nerve morphometry. Ann Neurol. 1980 Dec;8(6):590–596. doi: 10.1002/ana.410080608. [DOI] [PubMed] [Google Scholar]
  9. Gosselin S., Kyle R. A., Dyck P. J. Neuropathy associated with monoclonal gammopathies of undetermined significance. Ann Neurol. 1991 Jul;30(1):54–61. doi: 10.1002/ana.410300111. [DOI] [PubMed] [Google Scholar]
  10. Haas D. C., Tatum A. H. Plasmapheresis alleviates neuropathy accompanying IgM anti-myelin-associated glycoprotein paraproteinemia. Ann Neurol. 1988 Apr;23(4):394–396. doi: 10.1002/ana.410230415. [DOI] [PubMed] [Google Scholar]
  11. Hauttecoeur B., Schmitt C., Dubois C., Danon F., Brouet J. C. Reactivity of human monoclonal IgM with nerve glycosphingolipids. Clin Exp Immunol. 1990 May;80(2):181–185. doi: 10.1111/j.1365-2249.1990.tb05230.x. [DOI] [PMC free article] [PubMed] [Google Scholar]
  12. Hays A. P., Latov N., Takatsu M., Sherman W. H. Experimental demyelination of nerve induced by serum of patients with neuropathy and an anti-MAG IgM M-protein. Neurology. 1987 Feb;37(2):242–256. doi: 10.1212/wnl.37.2.242. [DOI] [PubMed] [Google Scholar]
  13. Hoang-Xuan K., Léger J. M., Ben Younes-Chennoufi A., Saidi H., Bouche P., Baumann N., Brunet P. Traitement des neuropathies dysimmunitaires par immunoglobulines polyvalentes intraveineuses. Etude ouverte de 16 cas. Rev Neurol (Paris) 1993;149(6-7):385–392. [PubMed] [Google Scholar]
  14. Jauberteau M. O., Henin D., Bouche P., Vallat J. M., Dumas M., Dellagi S., Leger J. M., Harpin M. L., Ratinahirana H., Chaunu M. P. Etude des anticorps antiglycolipides au cours des dysglobulinémies monoclonales à IgM associées à une neuropathie périphérique. Rev Neurol (Paris) 1988;144(8-9):474–480. [PubMed] [Google Scholar]
  15. Latov N., Sherman W. H., Nemni R., Galassi G., Shyong J. S., Penn A. S., Chess L., Olarte M. R., Rowland L. P., Osserman E. F. Plasma-cell dyscrasia and peripheral neuropathy with a monoclonal antibody to peripheral-nerve myelin. N Engl J Med. 1980 Sep 11;303(11):618–621. doi: 10.1056/NEJM198009113031105. [DOI] [PubMed] [Google Scholar]
  16. Mendell J. R., Sahenk Z., Whitaker J. N., Trapp B. D., Yates A. J., Griggs R. C., Quarles R. H. Polyneuropathy and IgM monoclonal gammopathy: studies on the pathogenetic role of anti-myelin-associated glycoprotein antibody. Ann Neurol. 1985 Mar;17(3):243–254. doi: 10.1002/ana.410170305. [DOI] [PubMed] [Google Scholar]
  17. Monaco S., Bonetti B., Ferrari S., Moretto G., Nardelli E., Tedesco F., Mollnes T. E., Nobile-Orazio E., Manfredini E., Bonazzi L. Complement-mediated demyelination in patients with IgM monoclonal gammopathy and polyneuropathy. N Engl J Med. 1990 Mar 8;322(10):649–652. doi: 10.1056/NEJM199003083221002. [DOI] [PubMed] [Google Scholar]
  18. Nobile-Orazio E., Baldini L., Barbieri S., Marmiroli P., Spagnol G., Francomano E., Scarlato G. Treatment of patients with neuropathy and anti-MAG IgM M-proteins. Ann Neurol. 1988 Jul;24(1):93–97. doi: 10.1002/ana.410240118. [DOI] [PubMed] [Google Scholar]
  19. Smith I. S., Kahn S. N., Lacey B. W., King R. H., Eames R. A., Whybrew D. J., Thomas P. K. Chronic demyelinating neuropathy associated with benign IgM paraproteinaemia. Brain. 1983 Mar;106(Pt 1):169–195. doi: 10.1093/brain/106.1.169. [DOI] [PubMed] [Google Scholar]
  20. Steck A. J., Murray N., Dellagi K., Brouet J. C., Seligmann M. Peripheral neuropathy associated with monoclonal IgM autoantibody. Ann Neurol. 1987 Dec;22(6):764–767. doi: 10.1002/ana.410220614. [DOI] [PubMed] [Google Scholar]
  21. Tatum A. H. Experimental paraprotein neuropathy, demyelination by passive transfer of human IgM anti-myelin-associated glycoprotein. Ann Neurol. 1993 May;33(5):502–506. doi: 10.1002/ana.410330514. [DOI] [PubMed] [Google Scholar]
  22. Younes-Chennoufi A. B., Léger J. M., Hauw J. J., Preud'homme J. L., Bouche P., Aucouturier P., Ratinahirana H., Lubetzki C., Lyon-Caen O., Baumann N. Ganglioside GD1b is the target antigen for a biclonal IgM in a case of sensory-motor axonal polyneuropathy: involvement of N-acetylneuraminic acid in the epitope. Ann Neurol. 1992 Jul;32(1):18–23. doi: 10.1002/ana.410320105. [DOI] [PubMed] [Google Scholar]

Articles from Journal of Neurology, Neurosurgery, and Psychiatry are provided here courtesy of BMJ Publishing Group

RESOURCES